Navigation Links
Hoffmann® II Hybrid

ProductsHoffmann® II Hybrid
Company Stryker Corporation
Item Hoffmann® II Hybrid
Features 
  • The system is easy to use because the components are modular in design allowing final fracture reduction after the frame is assembled
  • The Hoffmann® II Hybrid is the only system that allows free hand wire placement prior to attaching the carbon fiber ring
  • The exclusive snap-fit component technology of the Hoffmann® II Hybrid makes frame assembly fast and intra-operative adjustment simple
  • Open rings designed to conform to anatomy for optimal clearance from the skin negating the need to try different rings.
  • Dedicated hybrid instruments that aid in reducing surgery time
  • Versatility: Stainless steel ring clamps can be placed inside or outside of the ring for a wide range of options
  • Description The Hoffmann® II Hybrid External Fixation System incorporating TenXo™ Technology represents the next generation in hybrid fixation. It incorporates features requested by orthopedic trauma surgeons and is designed to offer speed of assembly by utilizing our exclusive patented Hoffmann® snap-fit technology.

    Using the Hoffmann® II Hybrid system is not a single surgeon operation due to the new tensioning device design. Tension can be maintained hands free while both hands make the final tightening of the clamps.
    Info Stryker Corporation
    Customer Service: (269) 385-2600
    Web site: http://www.stryker.com/

    Related medicine products :

    1. The Hoffmann® II For External Fixation
    2. Hoffmann® II Compact™
    3. Hybrid Fixator
    4. Hybrid Fixation System
    5. Periarticular Hybrid Fixator
    6. Hybridization Oven/Shaker 100 V, 60 Hz
    7. PersonalHyb Hybridization Oven, 100/120V
    8. PersonalHyb Hybridization Oven, 230V
    9. Hybridization Oven (110 V)
    10. Maxi 14 Hybridization Oven
    11. Hybridization Oven (220 V)
    Breaking Medicine News(10 mins):Health News:Unanimous Vote Creates Largest RN Union in U.S. History 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 3Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 4Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 5Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 2Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 3Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 4Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 5Health News:VitaminSpice Signs Agreement With Former CEO of Wal-Mart Stores Division for US Distribution 2Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 2Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 3Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 4Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 5